Stock analysis · Bull Rankings model

HSIC analysis

Henry Schein, Inc.Medical Distribution. Scored on the same transparent model behind the daily rankings.

HSIC
Henry Schein, Inc. · Medical Distribution
FCF$569mC+
Rev+6.5%C+
D/E0.81C+
P/E25.8xB
PEG2.04C
53.4Score
$88.50$9.9B
1Y Target$98.19Analyst consensus · 16 analysts
5Y Target$143.76Compound horizon
10Y Target$213.25Long-dated conviction
FCF$569mTTM
C+
FCF $569m — respectable but not differentiating
Rev+6.5%TTM YoY
C+
Revenue +6.5% — steady but below market-beating range
D/E0.81
C+
D/E 0.81 — above the Healthcare debt median (≈75th pctile)
P/E25.8x
B
P/E 25.8 — near the Healthcare median (≈60th pctile)
PEG2.04
C
PEG 2.04 — expensive relative to growth rate

Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.

Quality-growth score · 53.4
Quality62.7
Growth70.1
Value34.8
Why this score
  • Buying back stock
Entry · Margin of safety
52-week rangeNear 52-week high
4% off the 12-month high
vs DCF fair value17% belowest. fair value ~$107
What the price assumes: free cash flow compounding at ~3% a year for the next decade — vs the ~12% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability37% · B+gross profit ÷ total assets (Novy-Marx)
ROIC11.6% · Breturn on invested capital — not score-weighted

Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.

Why now
Medical Distribution · market cap $9.9b. 4% off the 52-week high of $92.18. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $98.19 (implying +11% upside).
Moat
ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 134% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Net margin 3.1% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon
1-3 yr $98.19 (16-analyst consensus) — fundamentals + valuation re-rating. 5 yr $143.76 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $213.25 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

HSIC vs the Top Picks average

PillarHSICBook avgDiff
Quality0.630.84-0.21
Growth0.700.84-0.14
Value0.350.78-0.44

Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.

Trend
+2.3 over 46 daily scores
From 51.1 (Jun 22) → 53.4 (now)

One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.

Analyst estimate revisions

30-day change+1.5%
90-day change+1.5%
Forward EPS estimate$6.00

Over the last 90 days, what analysts expect HSIC to earn is drifting higher (+1.5%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.

A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →

Shares to buy
22
Position size
$1,947
3.9% of portfolio
Stop price
$66.38
25% below $88.50
$ at risk if stopped
$486.75
budget $500.00 · 1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

Henry Schein, Inc. (HSIC): score, valuation & FAQ

Henry Schein, Inc. (HSIC) is a Medical Distribution company that scores 53.4 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.

On valuation, HSIC sits about 17% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 3% annual free-cash-flow growth over the next decade.

Is HSIC a good stock to buy?

Bull Rankings scores HSIC 53.4 out of 100 on its quality-growth model, which is a middling reading. A score is a quantitative screen of Henry Schein, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.

Why does HSIC score 53.4 on Bull Rankings?

The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). HSIC grades middle-of-pack across the strip. Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.

Is HSIC overvalued or undervalued?

Based on $88.50, HSIC sits about 17% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 3% annual free-cash-flow growth over the next decade. It trades at a 25.8x P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.

What are the main risks of investing in HSIC?

Net margin 3.1% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.

New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.

Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.

More Medical Distribution stocks by score

All Healthcare rankings →

Analyze another ticker →